BioNano Genomics, Inc. (BNGO)
|Net Income (ttm)||-40.54M|
|Trading Day||July 23|
|Day's Range||5.88 - 6.17|
|52-Week Range||0.47 - 15.69|
Bionano Genomics is risky and its valuation does not justify its price. There is no compelling argument for a buy in BNGO stock.
With Bionano's disruptive tool, Saphyr, poised to revolutionize the DNA analysis sector, investors should definitely look to buy BNGO stock on its recent dip. The post You'd Be Wrong to Paint Bionano Ge...
The market's pessimism about these diagnostics stocks appeared unrelated to company-specific news.
Bionano Genomics Announces Back-to-Back Publications in the American Journal of Human Genetics that Compare Optical G...
SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that two peer-reviewed studies from world renowned scientists and clinicians from prestigious instituti...
Analysts for these sought-after companies foresee upside ranging from 105% to 144% over the next year.
Bionano Genomics, Inc. (BNGO) closed the most recent trading day at $6.72, moving -1.47% from the previous trading session.
Bionano Genomics' Chief Medical Officer Dr. Alka Chaubey and Cancer Genomics Consortium President Dr. Yassmine Akkari...
SAN DIEGO, July 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Chief Medical Officer Dr. Alka Chaubey and current President of the Cancer Genomics Consortium Dr....
SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the 2021 Ladenburg Thalmann Healthcare Conference bei...
Current & Former Penny Stocks With High Marks From Analysts Right Now. The post 7 Hot Penny Stocks Analysts Like To Watch In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...
BNGO stock has established a reliable trading range. Even long-term investors can game it while they wait for their long-term reward.
Bionano Genomics (BNGO) stock is getting a boost on Monday from a couple of new pieces of news that traders will want to know. The post BNGO Stock: 2 Big Reasons Bionano Genomics Fans Should Be Cheering...
With the "story" behind it still years in the making, take your time with BNGO stock. At some point, its meme stock investors will cash out, sending it back to more reasonable prices.
Gene editing stocks are getting a boost on Monday morning after Intellia Therapeutics said it was successful using CRISPR gene-editing therapy directed inside the body to an internal organ. The post Gen...
A popular trade on social media, BNGO stock has some bullish catalysts. But the primary spark, the short squeeze, might not fire.
As Bionano's Saphyr system gains international recognition, BNGO stock deserves another chance at breaking through $15 and beyond. The post Geographic Expansion Enables Healthy Diagnosis for Bionano Gen...
In the latest trading session, Bionano Genomics, Inc. (BNGO) closed at $7.15, marking a -1.38% move from the previous day.
Solid revenue and earnings growth prospects of AMC, AHT and BNGO make them relatively safer bets despite being favorites of retail trades on the meme frenzy.
BNGO stock looks decent until you dive deeper and understand what's really going on. The shares' outlook isn't good.
Bionano Genomics offers a system called Saphyr that does optical genetic sequencing. If the technique floods the market, it could be a winner.
BTIG analyst Sung Ji Nam recently initiated coverage of Bionano Genomics with a buy rating and a price target of $10. Is BNGO stock a buy?
They're gaining this year. But the best may be yet to come.
These healthcare stocks are at the forefront of huge trends, including precision medicine and advances in diagnosis technologies. The post 5 Healthcare Stocks to Buy for Their Game-Changing Potential ap...
Does this gene-testing biotech company have value as more than a short-squeeze play?
The genetic testing specialist is bolstering its leadership ranks.
AMC stock ignites momentum in small cap penny stocks this month. The post Hot Penny Stocks To Watch As AMC Stock Ignites Small Caps In June appeared first on Penny Stocks to Buy, Picks, News and Informa...
Bionano Genomics Inc. (NASDAQ: BNGO) shares climbed higher Monday after the company appointed Jason Priar as its Chief Commercial Officer. Priar was formerly a sales leader at GeneDx, Sema4, and PerkinE...
BNGO stock is gaining on Monday thanks to r/WallStreetBets interest and a new corporate higher bringing a wealth of experience. The post BNGO Stock: The Big News Lifting Bionano Genomics This Morning ap...
Bionano Genomics Appoints Jason Priar, Former GeneDx, Sema4 and PerkinElmer Genomics Sales Leader, as its Chief Comme...
SAN DIEGO, June 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Jason Priar has joined the company as its Chief Commercial Officer. Jason is a seasoned sales lead...
Today, amid an overall red day for meme stocks, BNGO stock has soared as speculation begins to build this could be the next short squeeze. The post BNGO Stock: r/WallStreetBets Is Betting Big on a Short...
Demand for Bionano's Saphyr tool is climbing, while new, potentially life-saving uses are being found for it. BNGO stock remains a buy.
This provider of genome mapping tools is showing signs of exponential growth ahead.
Bionano Genomics will have to show how its products are different than the competition if BNGO stock is to hold on to its recent gains. The post The Bear Case For Bionano Genomics Carries More Weight ap...
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the Oppenheimer MedTech, Tools & Diagnostics Summit be...
Bionano Genomics recently reported healthy Saphyr Systems sales in the first quarter. As a result, BNGO stock gained over 20%.
Penny stocks remain volatile but these analysts have a bright outlook on these The post 5 Penny Stocks To Watch Right Now That Analysts Are Bullish On appeared first on Penny Stocks to Buy, Picks, News ...
Are these popular momentum stocks too cheap to ignore or blatant value traps?
Bionano Genomics can't kick the cash-raising bug. BNGO stock could fall to $1.85, its potential cash per share if it continues to raise cash.
The company reported better-than-expected Q1 revenue growth.
Bionano Genomics, Inc. (NASDAQ: BNGO), CorMedix Inc. (NASDAQ: CRMD) and Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) are among the health care movers Friday. Bionano Moves On Q1 Results: Bionano reported ...
These seven risky Reddit penny stocks are in the biotech space and the business of developing cancer therapies and treatments. The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on I...
These penny stocks gapped up big this morning; are they worth watching? The post 3 Penny Stocks That Gapped Up Big in Early Morning Trading appeared first on Penny Stocks to Buy, Picks, News and Informa...
The company delivered a pleasant surprise.
Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of 0.00% and 13.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
BioNano Genomics Inc (NASDAQ:BNGO) shares traded higher by 6.9% to $4.41 after the company reported better-than-expected first-quarter sales results. Bionano Genomics reported quarterly sales of $3.2 mi...
Bionano Genomics Reports First Quarter 2021 Financial Results and Highlights Recent Business Progress
SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today reported financial results and business achievements for the first quarter ended March 31, 2021 and highlighted re...
BioNano Genomics (NASDAQ:BNGO) is testing an important support at the $5 level. If this support breaks, shares could make a rapid and large move lower.
Don't mistake Bionano for just any Reddit stock. With its Q1 earnings looming, BNGO stock is attractively priced near its 2021 low.
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers ... [Read more...]
Diagnostics & Research
|IPO Date |
Aug 21, 2018
R. Erik Holmlin
|Stock Exchange |
|Ticker Symbol |
In 2020, BNGO's revenue was $8.50 million, a decrease of -16.06% compared to the previous year's $10.13 million. Losses were -$41.11 million, 37.9% more than in 2019.
According to 4 analysts, the average rating for BNGO stock is "Buy." The 12-month stock price forecast is 11.50, which is an increase of 92.63% from the latest price.